Skip to content

Text Size: AAA

Investors

Printer Friendly Version Print  |  E-mail this page Email  |  E-mail Alerts Alerts  |  RSS RSS  |  View contacts Contacts  |  Download Financial Tear Sheet Tear Sheet

Webcast ImageWebcast
Amylin Pharmaceuticals, Inc. Corporate Update (Live)
01/27/12 at 4:30 p.m. ET
Our Investor Relations Center is provided to give you convenient access to company information, including financial reports, press releases and corporate events. You can also sign up to be reminded via email of any upcoming company presentations, or to be notified of news releases and other announcements.

If you cannot find the information you're looking for on our website please let us know, and we will do our best to accommodate your request.
Featured Report
Download Documentation 2010 Annual Report
RECEIVE E-MAIL ALERTS
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
Stock Quote
AMLN (Common)
ExchangeNASDAQ (US Dollar)
Price$12.14
Change (%) Stock is Up 0.20 (1.68%)
Volume6,249,578
Data as of 01/27/12 1:54 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore
DateTitle 
01/27/12FDA Approves BYDUREON™ -- The First and Only Once-Weekly Treatment for Type 2 Diabetes
Provides Glycemic Control in a Once-Weekly Dose SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON™ (exenatide extended-release for injectable suspension) – the first once-weekly treatment for type 2 diabetes. BYDUREON is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to ... 
Printer Friendly Version
01/09/12Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates
2012 Corporate Priorities Unveiled at J.P. Morgan Healthcare Conference   SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today outlined its key strategic priorities for 2012, with a strong focus on driving the global commercial value of its diabetes franchise. In a presentation at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, Amylin President and Chief Executive Officer Daniel M. Bradbury highlighted steps the compan... 
Printer Friendly Version
01/03/12Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 5:00 p.m. ET / 2:00 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview. The presentation and break-out session will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a r... 
Printer Friendly Version
11/23/11Amylin Pharmaceuticals to Present at the 23rd Annual Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 23, 2011 /PRNewswire via COMTEX/ --Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 23rd Annual Piper Jaffray Health Care Conference in New York on Wednesday, November 30, 2011 at 1:00 p.m. ET/10:00 a.m. PT. Mark Foletta, Senior Vice President and Chief Financial Officer, Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a r... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.